[Preclinical assay of candid #1 vaccine against Argentine Hemorrhagic Fever made in Argentina].
Candid #1 vaccine against Argentine Hemorrhagic Fever produced in USA versus lots of the same vaccine made in Argentina were compared in guinea pigs regarding safety, immunogenicity and protective efficacy against a challenge with pathogenic Junin virus. Lots No Exp 3, 7A and 8A of Argentine origin as well as lot TSI 5-1-92 from USA were inoculated in guinea pigs of 250-400 g in two consecutive assays. Ten animals inoculated with saline performed as normal controls in each experiment. Parameters studied were: a) temperature; b) body weight; c) neutralizing antibodies to Junin virus; d) response to viral challenge. Animals gained weight and remained normothermic up to the challenge. Guinea pigs that received Candid #1 from any manufacturer elicited neutralizing antibodies to Junin virus (titles from 40 to 81920) and survived to challenge whilst 8/10 animals died in each control group. Data presented demonstrated that Candid #1 vaccines from USA or Argentine manufacturers were equally safe, immunogenic and protective in guinea pigs.
Ambrosio
Ana M
AM
Instituto Nacional de Enfermedades Virales Humanas Dr. J.I. Maiztegui, Monteagudo 2510, 2700 Pergamino, Provincia de Buenos Aires, Argentina. anaambrosio@yahoo.com.ar
Riera
Laura M
LM
Saavedra
María del Carmen
Mdel C
Sottosanti
María J
MJ
D000818:Animals; D001118:Argentina; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006478:Hemorrhagic Fever, American / Q000276:immunology / Q000517:prevention & control*; D018051:Junin virus / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D014613:Vaccines, Attenuated; D014765:Viral Vaccines